Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
While the White House focused its initial Section 232 pharmaceutical tariffs on branded drugs, generics makers—who supply the vast majority of U.S. | While the White House focused its initial Section 232 pharmaceutical tariffs on branded drugs, generics makers—who supply the vast majority of U.S. prescriptions—won’t stay in the clear for long.
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise

Donald Trump’s 200% tariffs on pharma: Why India’s generic medicines could still remain competitive

Pharma companies in a flux over Trump's 200% tariff move on generics

UBS Warns Trump's 100% Generic Drug Tariff Puts Indian Pharma "On Notice"; Goldman Flags Reshoring Winners

Trump proposes 100% tariffs on imported generic drugs starting 2028, with 200% penalties to follow

Trump announces new generic drugs tariff plan: No tariffs for 2 years, then 100%, and then 200%

Trump’s 200% generic tariff threat would imperil Americans: Indian pharma

Trump's 200% drug tariff plan: Is India's pharma industry about to face an economic storm?

Trump Sets August 1 Start for Generic Drug Tariff Clock, Warns of 200% Duties: Companies Must 'Build Plan

Trump threatens tariffs on imported generic drugs

Trump's generic drugs tariff threatens Indian pharma's top market

In a blow to India’s pharmaceutical industry, the Donald Trump administration has announced up to 200% tariffs on generic drugs…

When President Donald Trump rolled out his plan to levy a 100% tariff rate on patented pharmaceutical products and ingredients…

India's $30-billion pharma industry is staring at a fresh challenge after US President Donald Trump announced that generic…

With questions already swirling about the actual affordability impact of t | With questions already swirling about the actual…

"For our generics coverage, we view the group as relatively well-positioned given: AMRX (significant US infrastructure), TEVA..."

Trump announces 100% tariffs on imported generic drugs starting August 2028, escalating to 200% in 2029, aiming to reshore US…